Dr. Yi Chen is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biotechnology and the pharmaceutical sectors. Dr. Chen’s research covers investment opportunities in the U.S. healthcare industry. Prior to joining H.C. Wainwright, Dr. Chen worked as an Associate Director of Equity Research at Aegis Capital Corp. and as a Research Associate at Morgan Joseph TriArtisan, LLC. Dr. Chen also worked as a Trading Associate at Zhang Capital Management, a New York-based buy-side fund. Prior to that, Dr. Chen was a Research Associate at the City University of New York where his research focused primarily on protein signaling domains utilizing an RNA interference approach.
Dr. Chen published several articles in leading peer-reviewed journals, presented research at various scientific conferences, and taught biology courses at Hunter College in New York City. Dr. Chen’s educational background includes a Ph.D. in biochemistry from the City University of New York and a B.S. in Biophysics from Fudan University. Dr. Chen is also a Chartered Financial Analyst (CFA) charterholder.